Literature DB >> 31108008

Potency Analysis of Mesenchymal Stromal Cells Using a Phospho-STAT Matrix Loop Analytical Approach.

Raghavan Chinnadurai1, Augustine Rajakumar2, Andrew J Schneider1, Wade A Bushman1, Peiman Hematti1, Jacques Galipeau1.   

Abstract

Potency assays for mesenchymal stromal cells (MSCs) need to be defined in advanced clinical trials. Here, we have developed an assay matrix approach that captures the signal transducer and activator of transcription (STAT) phosphorylation of MSCs upon stimulation with their combined secretome that arose with the interaction of activated peripheral blood mononuclear cells (PBMCs). Secretome of heat-inactivated (HI) MSCs cocultured with and without activated PBMCs was used as an internal reference. We have compared the short-term phosphorylation status of STAT1, STAT3, STAT4, STAT5, and STAT6 on MSCs derived from human bone marrow, adipose tissue, and umbilical cord using phosflow technology. Secretome of live MSCs cocultured with activated PBMCs downregulate STAT1 and STAT3 phosphorylation on MSCs, whereas the secretome of HI-MSCs or PBMCs do not. Thus, investigation of the combined secretome of MSC and PBMC interaction on MSCs determine the potency of MSCs as the generator and sensor of the secretome. Bone marrow, adipose, and umbilical cord MSCs are comparable in modulating STAT1 and STAT3 responses. Measurements of STAT1 and STAT3 phosphorylation on MSCs as responder cells correlate and predict allogeneic T-cell suppression. Our comparative phosphomatrix approach between live and reference HI-MSCs defines the potency of MSCs as both stimulators and responders as part of a robust platform for predictive potency analysis. Stem Cells 2019;37:1119-1125. © AlphaMed Press 2019.

Entities:  

Keywords:  Assay matrix; Immune suppression; Mesenchymal stromal cells; Phosflow; Phospho-STAT; Potency analysis

Mesh:

Substances:

Year:  2019        PMID: 31108008      PMCID: PMC6729138          DOI: 10.1002/stem.3035

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  23 in total

1.  Towards the creation of a standard MSC line as a calibration tool.

Authors:  Robert Deans
Journal:  Cytotherapy       Date:  2015-09       Impact factor: 5.414

Review 2.  Research using Mesenchymal Stem/Stromal Cells: quality metric towards developing a reference material.

Authors:  Vivek Tanavde; Candida Vaz; Mahendra S Rao; Mohan C Vemuri; Radhika R Pochampally
Journal:  Cytotherapy       Date:  2015-09       Impact factor: 5.414

3.  Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement.

Authors:  M Dominici; K Le Blanc; I Mueller; I Slaper-Cortenbach; Fc Marini; Ds Krause; Rj Deans; A Keating; Dj Prockop; Em Horwitz
Journal:  Cytotherapy       Date:  2006       Impact factor: 5.414

4.  The challenge of defining mesenchymal stromal cell potency assays and their potential use as release criteria.

Authors:  Jacques Galipeau; Mauro Krampera
Journal:  Cytotherapy       Date:  2015-02       Impact factor: 5.414

5.  MSC-based product characterization for clinical trials: an FDA perspective.

Authors:  Michael Mendicino; Alexander M Bailey; Keith Wonnacott; Raj K Puri; Steven R Bauer
Journal:  Cell Stem Cell       Date:  2014-02-06       Impact factor: 24.633

6.  Characterization of mesenchymal stromal cells: potency assay development.

Authors:  Peiman Hematti
Journal:  Transfusion       Date:  2016-04       Impact factor: 3.157

7.  Morphological features of IFN-γ-stimulated mesenchymal stromal cells predict overall immunosuppressive capacity.

Authors:  Matthew W Klinker; Ross A Marklein; Jessica L Lo Surdo; Cheng-Hong Wei; Steven R Bauer
Journal:  Proc Natl Acad Sci U S A       Date:  2017-03-10       Impact factor: 11.205

8.  Potency Analysis of Mesenchymal Stromal Cells Using a Combinatorial Assay Matrix Approach.

Authors:  Raghavan Chinnadurai; Devi Rajan; Muna Qayed; Dalia Arafat; Marco Garcia; Yifei Liu; Subra Kugathasan; Larry J Anderson; Greg Gibson; Jacques Galipeau
Journal:  Cell Rep       Date:  2018-02-27       Impact factor: 9.423

9.  Intramuscular administration potentiates extended dwell time of mesenchymal stromal cells compared to other routes.

Authors:  Lorena R Braid; Catherine A Wood; Danielle M Wiese; Barry N Ford
Journal:  Cytotherapy       Date:  2017-11-20       Impact factor: 5.414

10.  Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock response and impaired interferon-γ licensing.

Authors:  Moïra François; Ian B Copland; Shala Yuan; Raphaëlle Romieu-Mourez; Edmund K Waller; Jacques Galipeau
Journal:  Cytotherapy       Date:  2011-10-27       Impact factor: 5.414

View more
  11 in total

1.  Use of MSCs and MSC-educated macrophages to mitigate hematopoietic acute radiation syndrome.

Authors:  Raghavan Chinnadurai; Matthew H Forsberg; John A Kink; Peiman Hematti; Christian M Capitini
Journal:  Curr Stem Cell Rep       Date:  2020-08-08

2.  Ruxolitinib Inhibits IFNγ Licensing of Human Bone Marrow Derived Mesenchymal Stromal Cells.

Authors:  Molly Mercedes Ryan; Mihir Patel; Keenan Hogan; Ariel Joy Lipat; Rafaela Scandolara; Rahul Das; Charles Bruker; Jacques Galipeau; Raghavan Chinnadurai
Journal:  Transplant Cell Ther       Date:  2021-02-04

3.  Preclinical Evaluation of the Safety and Efficacy of Cryopreserved Bone Marrow Mesenchymal Stromal Cells for Corneal Repair.

Authors:  Ilham Putra; Xiang Shen; Khandaker N Anwar; Behnam Rabiee; Ravand Samaeekia; Enmar Almazyad; Pushpanjali Giri; Sayena Jabbehdari; Mohammed R Hayat; Abdelrahman M Elhusseiny; Mahmood Ghassemi; Nadim Mahmud; Deepak P Edward; Charlotte E Joslin; Mark I Rosenblatt; Reza Dana; Medi Eslani; Peiman Hematti; Ali R Djalilian
Journal:  Transl Vis Sci Technol       Date:  2021-08-12       Impact factor: 3.283

4.  IFN-γ and PPARδ influence the efficacy and retention of multipotent adult progenitor cells in graft vs host disease.

Authors:  Fiona Carty; Hazel Dunbar; Ian J Hawthorne; Anthony E Ting; Samantha R Stubblefield; Wouter Van't Hof; Karen English
Journal:  Stem Cells Transl Med       Date:  2021-08-16       Impact factor: 6.940

Review 5.  Advancing Treatment of Bone Metastases through Novel Translational Approaches Targeting the Bone Microenvironment.

Authors:  Nan Sethakorn; Erika Heninger; Cristina Sánchez-de-Diego; Adeline B Ding; Ravi Chandra Yada; Sheena C Kerr; David Kosoff; David J Beebe; Joshua M Lang
Journal:  Cancers (Basel)       Date:  2022-02-01       Impact factor: 6.639

Review 6.  Potential mechanisms and therapeutic targets of mesenchymal stem cell transplantation for ischemic stroke.

Authors:  Li Zhou; Huimin Zhu; Xue Bai; Jiagui Huang; Yue Chen; Jun Wen; Xuemei Li; Bowen Wu; Yongjun Tan; Mingfen Tian; Jiangxia Ren; Mengxia Li; Qin Yang
Journal:  Stem Cell Res Ther       Date:  2022-05-12       Impact factor: 8.079

7.  Integrated analysis of the tumor microenvironment using a reconfigurable microfluidic cell culture platform.

Authors:  Nan Sethakorn; Erika Heninger; Matthew T Breneman; Emma Recchia; Adeline B Ding; David F Jarrard; Peiman Hematti; David J Beebe; David Kosoff
Journal:  FASEB J       Date:  2022-10       Impact factor: 5.834

8.  A STAT5-Smad3 dyad regulates adipogenic plasticity of visceral adipose mesenchymal stromal cells during chronic inflammation.

Authors:  Jayeeta Giri; Pradyut K Paul; Rahul Das; Nicole Froelich; Raghavan Chinnadurai; Sara McCoy; Wade Bushman; Jacques Galipeau
Journal:  NPJ Regen Med       Date:  2022-08-31

Review 9.  Recent advances in understanding mesenchymal stromal cells.

Authors:  Erika Rendra; Eleonora Scaccia; Karen Bieback
Journal:  F1000Res       Date:  2020-02-27

10.  Sub-nanoliter metabolomics via mass spectrometry to characterize volume-limited samples.

Authors:  Yafeng Li; Marcos Bouza; Changsheng Wu; Hengyu Guo; Danning Huang; Gilad Doron; Johnna S Temenoff; Arlene A Stecenko; Zhong Lin Wang; Facundo M Fernández
Journal:  Nat Commun       Date:  2020-11-06       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.